[{"submitter_treatment_id":"TREATMENT_1","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Endoscopic therapy","Photodynamic therapy"],"is_primary_treatment":"Yes","treatment_start_date":"2021-02","treatment_end_date":"2022-09","treatment_setting":"Neoadjuvant","treatment_intent":"Palliative","days_per_cycle":1,"number_of_cycles":3,"response_to_treatment_criteria_method":"Cheson CLL 2012 Oncology Response Criteria","response_to_treatment":"Stable disease"},
{"submitter_treatment_id":"TREATMENT_2","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Radiation therapy","Bone marrow transplant","Surgery"],"is_primary_treatment":"Yes","treatment_start_date":"2021-09","treatment_end_date":"2022-05","treatment_setting":"Not applicable","treatment_intent":"Curative","days_per_cycle":2,"number_of_cycles":3,"response_to_treatment_criteria_method":"Response Assessment in Neuro-Oncology (RANO)","response_to_treatment":"Minor response"},
{"submitter_treatment_id":"TREATMENT_3","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["No treatment","Hormonal therapy","Other targeting molecular therapy"],"is_primary_treatment":"Yes","treatment_start_date":"2021-03","treatment_end_date":"2022-10","treatment_setting":"Adjuvant","treatment_intent":"Palliative","days_per_cycle":1,"number_of_cycles":4,"response_to_treatment_criteria_method":"Cheson CLL 2012 Oncology Response Criteria","response_to_treatment":"Immune partial response (iPR)"},
{"submitter_treatment_id":"TREATMENT_4","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Chemotherapy","Ablation"],"is_primary_treatment":"Yes","treatment_start_date":"2021-06","treatment_end_date":"2022-05","treatment_setting":"Not applicable","treatment_intent":"Curative","days_per_cycle":7,"number_of_cycles":3,"response_to_treatment_criteria_method":"iRECIST","response_to_treatment":"Progressive disease"},
{"submitter_treatment_id":"TREATMENT_5","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Immunotherapy"],"is_primary_treatment":"No","treatment_start_date":"2021-10","treatment_end_date":"2022-04","treatment_setting":"Adjuvant","treatment_intent":"Curative","days_per_cycle":2,"number_of_cycles":5,"response_to_treatment_criteria_method":"iRECIST","response_to_treatment":"Complete remission with incomplete hematologic recovery (CRi)"},
{"submitter_treatment_id":"TREATMENT_6","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Radiation therapy","Ablation"],"is_primary_treatment":"Unknown","treatment_start_date":"2021-03","treatment_end_date":"2022-09","treatment_setting":"Adjuvant","treatment_intent":"Curative","days_per_cycle":6,"number_of_cycles":3,"response_to_treatment_criteria_method":"Physician Assessed Response Criteria","response_to_treatment":"Immune stable disease (iSD)"},
{"submitter_treatment_id":"TREATMENT_7","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Chemotherapy","Ablation","Bone marrow transplant"],"is_primary_treatment":"No","treatment_start_date":"2021-06","treatment_end_date":"2022-03","treatment_setting":"Not applicable","treatment_intent":"Curative","days_per_cycle":3,"number_of_cycles":3,"response_to_treatment_criteria_method":"Cheson CLL 2012 Oncology Response Criteria","response_to_treatment":"Molecular relapse (after CR MRD-)"},
{"submitter_treatment_id":"TREATMENT_8","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Bone marrow transplant","Ablation"],"is_primary_treatment":"Yes","treatment_start_date":"2021-03","treatment_end_date":"2022-10","treatment_setting":"Not applicable","treatment_intent":"Palliative","days_per_cycle":1,"number_of_cycles":5,"response_to_treatment_criteria_method":"AML Response Criteria","response_to_treatment":"Minor response"},
{"submitter_treatment_id":"TREATMENT_9","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Radiation therapy","Photodynamic therapy","Endoscopic therapy"],"is_primary_treatment":"Unknown","treatment_start_date":"2021-07","treatment_end_date":"2022-07","treatment_setting":"Adjuvant","treatment_intent":"Curative","days_per_cycle":7,"number_of_cycles":4,"response_to_treatment_criteria_method":"iRECIST","response_to_treatment":"Complete remission without measurable residual disease (CR MRD-)"},
{"submitter_treatment_id":"TREATMENT_10","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["No treatment"],"is_primary_treatment":"No","treatment_start_date":"2021-12","treatment_end_date":"2022-08","treatment_setting":"Adjuvant","treatment_intent":"Curative","days_per_cycle":3,"number_of_cycles":3,"response_to_treatment_criteria_method":"iRECIST","response_to_treatment":"Minor response"},
{"submitter_treatment_id":"TREATMENT_11","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Other targeting molecular therapy","Photodynamic therapy","No treatment"],"is_primary_treatment":"No","treatment_start_date":"2021-12","treatment_end_date":"2022-07","treatment_setting":"Not applicable","treatment_intent":"Curative","days_per_cycle":4,"number_of_cycles":3,"response_to_treatment_criteria_method":"iRECIST","response_to_treatment":"Immune partial response (iPR)"},
{"submitter_treatment_id":"TREATMENT_12","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Bone marrow transplant","Stem cell transplant"],"is_primary_treatment":"No","treatment_start_date":"2021-10","treatment_end_date":"2022-10","treatment_setting":"Advanced/Metastatic","treatment_intent":"Palliative","days_per_cycle":6,"number_of_cycles":4,"response_to_treatment_criteria_method":"Physician Assessed Response Criteria","response_to_treatment":"Complete remission without measurable residual disease (CR MRD-)"},
{"submitter_treatment_id":"TREATMENT_13","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Photodynamic therapy"],"is_primary_treatment":"Yes","treatment_start_date":"2021-09","treatment_end_date":"2022-05","treatment_setting":"Advanced/Metastatic","treatment_intent":"Curative","days_per_cycle":3,"number_of_cycles":5,"response_to_treatment_criteria_method":"RECIST 1.1","response_to_treatment":"Immune stable disease (iSD)"},
{"submitter_treatment_id":"TREATMENT_14","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Endoscopic therapy","Bone marrow transplant"],"is_primary_treatment":"Yes","treatment_start_date":"2021-03","treatment_end_date":"2022-01","treatment_setting":"Advanced/Metastatic","treatment_intent":"Curative","days_per_cycle":4,"number_of_cycles":4,"response_to_treatment_criteria_method":"Cheson CLL 2012 Oncology Response Criteria","response_to_treatment":"No evidence of disease (NED)"},
{"submitter_treatment_id":"TREATMENT_15","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Radiation therapy","No treatment"],"is_primary_treatment":"Yes","treatment_start_date":"2021-06","treatment_end_date":"2022-03","treatment_setting":"Not applicable","treatment_intent":"Curative","days_per_cycle":3,"number_of_cycles":5,"response_to_treatment_criteria_method":"AML Response Criteria","response_to_treatment":"Physician assessed stable disease"},
{"submitter_treatment_id":"TREATMENT_16","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Bone marrow transplant","Chemotherapy"],"is_primary_treatment":"No","treatment_start_date":"2021-06","treatment_end_date":"2022-10","treatment_setting":"Adjuvant","treatment_intent":"Curative","days_per_cycle":7,"number_of_cycles":4,"response_to_treatment_criteria_method":"Physician Assessed Response Criteria","response_to_treatment":"Complete remission with incomplete hematologic recovery (CRi)"},
{"submitter_treatment_id":"TREATMENT_17","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Other targeting molecular therapy"],"is_primary_treatment":"Yes","treatment_start_date":"2021-09","treatment_end_date":"2022-06","treatment_setting":"Not applicable","treatment_intent":"Curative","days_per_cycle":3,"number_of_cycles":4,"response_to_treatment_criteria_method":"Cheson CLL 2012 Oncology Response Criteria","response_to_treatment":"Immune stable disease (iSD)"},
{"submitter_treatment_id":"TREATMENT_18","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Bone marrow transplant"],"is_primary_treatment":"No","treatment_start_date":"2021-02","treatment_end_date":"2022-06","treatment_setting":"Adjuvant","treatment_intent":"Palliative","days_per_cycle":1,"number_of_cycles":4,"response_to_treatment_criteria_method":"Cheson CLL 2012 Oncology Response Criteria","response_to_treatment":"Partial response"},
{"submitter_treatment_id":"TREATMENT_19","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Bone marrow transplant"],"is_primary_treatment":"No","treatment_start_date":"2021-04","treatment_end_date":"2022-01","treatment_setting":"Advanced/Metastatic","treatment_intent":"Curative","days_per_cycle":1,"number_of_cycles":4,"response_to_treatment_criteria_method":"Response Assessment in Neuro-Oncology (RANO)","response_to_treatment":"Partial response"},
{"submitter_treatment_id":"TREATMENT_20","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Chemotherapy","Photodynamic therapy","Endoscopic therapy"],"is_primary_treatment":"Unknown","treatment_start_date":"2021-10","treatment_end_date":"2022-04","treatment_setting":"Adjuvant","treatment_intent":"Palliative","days_per_cycle":4,"number_of_cycles":5,"response_to_treatment_criteria_method":"iRECIST","response_to_treatment":"Molecular relapse (after CR MRD-)"},
{"submitter_treatment_id":"TREATMENT_21","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Other targeting molecular therapy"],"is_primary_treatment":"No","treatment_start_date":"2021-11","treatment_end_date":"2022-08","treatment_setting":"Neoadjuvant","treatment_intent":"Curative","days_per_cycle":5,"number_of_cycles":3,"response_to_treatment_criteria_method":"Response Assessment in Neuro-Oncology (RANO)","response_to_treatment":"Molecular relapse (after CR MRD-)"},
{"submitter_treatment_id":"TREATMENT_22","program_id":null,"submitter_donor_id":null,"submitter_primary_diagnosis_id":"","treatment_type":["Other targeting molecular therapy","Immunotherapy","No treatment"],"is_primary_treatment":"No","treatment_start_date":"2021-06","treatment_end_date":"2022-07","treatment_setting":"Advanced/Metastatic","treatment_intent":"Curative","days_per_cycle":4,"number_of_cycles":3,"response_to_treatment_criteria_method":"Response Assessment in Neuro-Oncology (RANO)","response_to_treatment":"No evidence of disease (NED)"}]